Literature DB >> 30243800

An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.

Andrea Necchi1, Patrizia Giannatempo2, Daniele Raggi2, Luigi Mariani2, Maurizio Colecchia2, Elena Farè2, Francesco Monopoli2, Giuseppina Calareso2, Siraj M Ali3, Jeffrey S Ross4, Jon H Chung3, Roberto Salvioni2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30243800     DOI： 10.1016/j.eururo.2018.09.010

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  18 in total

1.  Phase II study of avelumab in multiple relapsed/refractory germ cell cancer.

Authors:  M Mego; D Svetlovska; M Chovanec; M Rečkova; K Rejlekova; J Obertova; P Palacka; Z Sycova-Mila; U De Giorgi; J Mardiak
Journal:  Invest New Drugs       Date:  2019-06-01       Impact factor: 3.850

Review 2.  Genetics of testicular germ cell tumors.

Authors:  Nirmish Singla; John T Lafin; Rashed A Ghandour; Samuel Kaffenberger; James F Amatruda; Aditya Bagrodia
Journal:  Curr Opin Urol       Date:  2019-07       Impact factor: 2.309

Review 3.  Mediastinal germ cell tumours: where we are and where we are going-a narrative review.

Authors:  Laura Marandino; Ursula Maria Vogl
Journal:  Mediastinum       Date:  2022-03-25

4.  Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis.

Authors:  Yucai Wang; Shouhao Zhou; Fang Yang; Xinyue Qi; Xin Wang; Xiaoxiang Guan; Chan Shen; Narjust Duma; Jesus Vera Aguilera; Ashish Chintakuntlawar; Katharine A Price; Julian R Molina; Lance C Pagliaro; Thorvardur R Halfdanarson; Axel Grothey; Svetomir N Markovic; Grzegorz S Nowakowski; Stephen M Ansell; Michael L Wang
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

Review 5.  Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.

Authors:  Caterina Arru; Maria Rosaria De Miglio; Antonio Cossu; Maria Rosaria Muroni; Ciriaco Carru; Angelo Zinellu; Panagiotis Paliogiannis
Journal:  Adv Ther       Date:  2021-06-08       Impact factor: 3.845

6.  Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials.

Authors:  Bin Zhao; Hong Zhao; Jiaxin Zhao
Journal:  Ther Adv Med Oncol       Date:  2020-07-16       Impact factor: 8.168

7.  Expression of the immune checkpoint receptor TIGIT in seminoma.

Authors:  Andrea Hinsch; Niclas C Blessin; Ronald Simon; Martina Kluth; Kristine Fischer; Claudia Hube-Magg; Wenchao Li; Georgia Makrypidi-Fraune; Björn Wellge; Tim Mandelkow; Nicolaus F Debatin; Doris Höflmayer; Maximilian Lennartz; Guido Sauter; Jakob R Izbicki; Sarah Minner; Franziska Büscheck; Ria Uhlig; David Dum; Till Krech; Andreas M Luebke; Corinna Wittmer; Frank Jacobsen; Eike Burandt; Stefan Steurer; Waldemar Wilczak
Journal:  Oncol Lett       Date:  2019-05-31       Impact factor: 2.967

8.  Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers.

Authors:  João Lobo; Ângelo Rodrigues; Rita Guimarães; Mariana Cantante; Paula Lopes; Joaquina Maurício; Jorge Oliveira; Carmen Jerónimo; Rui Henrique
Journal:  Cancers (Basel)       Date:  2019-10-11       Impact factor: 6.639

Review 9.  Targeting the Immune system and Epigenetic Landscape of Urological Tumors.

Authors:  João Lobo; Carmen Jerónimo; Rui Henrique
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

Review 10.  Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of 'epidrugs'.

Authors:  Ana Rita Cardoso; João Lobo; Vera Miranda-Gonçalves; Rui Henrique; Carmen Jerónimo
Journal:  Epigenetics       Date:  2020-08-12       Impact factor: 4.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.